Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703326 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,144
- Enrollment target
NCT00703326 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,144 participants.
The verdict
NCT00703326, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,144 participants
- Enrollment target
Study Summary
The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.
Interventions
- OTHER Placebo
- DRUG docetaxel
- BIOLOGICAL ramucirumab (IMC-1121B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,144 participants |
| Start Date | 2008-08-06 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703326
The ClinicalTrials.gov registry entry for NCT00703326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00703326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703326 about?
NCT00703326 is a clinical study titled "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer". The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic...
What is the current status of trial NCT00703326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,144 participants. The study started on 2008-08-06. Estimated completion is 2020-11-19.
What interventions are being tested in trial NCT00703326?
The interventions under investigation include: Placebo (OTHER), docetaxel (DRUG), ramucirumab (IMC-1121B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00703326?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.